J-Pharma Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 2 of 2
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,173,990 | URAT1 Inhibitor In force · High confidence | In force | High confidence | |
| US 12,458,628 | Cancer therapeutic In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 2: 1 patent in force now held by others · 7 lapsed for an unpaid fee · 9 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 3 abandoned · 6 no status recorded
Showing 1 to 10 of 11, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/771,230 | Method of Treating Biliary Tract Cancer | Jul 12, 2024 | Pending |
| 17/169,033 | Feb 5, 2021 | No status recorded | |
| 17/638,680 | A Pharmaceutical Composition Used for a Patient Having Specific Genetic Marker | Aug 31, 2020 | Abandoned |
| 17/638,669 | A Pharmaceutical Composition for Treating Cancer Used for a Patient Having Specific Genetic Marker | Aug 31, 2020 | Pending |
| 16/328,214 | Mar 10, 2016 | No status recorded | |
| 14/899,572 | Blood-Based Biomarker for Cancer | Jun 9, 2015 | Abandoned |
| 13/325,574 | Dec 14, 2011 | No status recorded | |
| 12/658,612 | Feb 8, 2010 | No status recorded | |
| 12/228,769 | Aug 15, 2008 | Abandoned | |
| 12/526,062 | Feb 6, 2007 | No status recorded |
10 of 11 applications shown.
Pro members see all 11 published applications.